top of page

Hamid Masoudi


Anatomic Pathology



Hamid Masoudi


604-682-2344 ext 63046



Clinical Assistant Professor, UBC




I graduated from Isfahan University of Medical Sciences, Iran in 1992. I moved to Canada in 2002, entered UBC pathology Residency Program in 2006 and graduated in 2009. Currently, I am working at St. Paul's Hospital as an Anatomical pathologist.

Academic Background

  • MD, Isfahan University of Medical Sciences, Iran 1992

  • General Pathology, Isfahan University of Medical Sciences, Iran 2001

  • Postdoctoral Research Fellowship, UBC 2004

  • FRCPC General Pathology 2009

Expertise / Research Interests

  • Breast pathology

  • General pathology

  • Breast, colorectal and thyroid cancer research

Teaching Interests

  • Teaching pathology residents

  • Teaching UBC medical students


  • Halwani Y SM, Kojic LD, Chan SK, Phang TP, Masoudi H, Jones SJ, Nabi IR, Wiseman SM. Prognostic significance of autocrine motility factor receptor expression by colorectal cancer and lymph node metastases. Am J Surg (2015) 209 (5) 884-9.

  • Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones S, Laskin J, Wiseman SM. Loss of Beta-catenin Expression is Prognostic of Reduced Survival in Individuals Diagnosed with Resectable Non-small cell Lung Cancer. American Journal of Surgery. (2012) 203(5):654-659.

  • Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Hunstman DG, Wiseman SM. HER-3 Over-Expression is Prognostic of Reduced Breast Cancer Survival: A Study of 4,046 Patients. Annals of Surgery (2010) 251(6):1107-16.

  • Deen S, Griffin OL, Masoudi H, Gown A, Jones SJ, Wiseman SM. Anaplastic thyroid carcinoma exhibits intratumoral molecular homogeneity for a therapeutic target panel. Anticancer research. July 2009, 29(7):2437-44.

  • Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. Journal of thoracic oncology. (2009) 4(4):486-91.

  • Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Park E, Gee J, Jones HE, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. (2008) 15;68(24):10238-46.

  • Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease- specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. (2008) 16; 10(5).

  • Joshi B, Strugnell SS, Masoudi H, Goetz J, Kojic L, Leung S, Leung S, Wiseman S, Nabi IR. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. (2008) 15; 68(20).

  • Wiseman SM, Melck A, Masoudi H, Ghiadi F Goldstein L, Gown A, Jones SJ, Grifith OL. Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis. Ann Surg Oncol. (2008) 15(10) 2811-26.

  • Leung SP, Griffith OL, Masoudi H, Gown A, Jones S, Phang T, Wiseman SM. Clinical utility of type 1 growth factor receptor expression in colon cancer. Am J Surg. (2008) 195 (5) 604-610.

  • Wiseman SM, Melck A, Masoudi H, Griffith OL, Gown A, Nabi IR, Jones SJ. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Am J Surg. (2008) 195 (5) 667-7

  • Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, BugisS, Jones SJ, Wiseman SM. Ann Surg Oncol. (2007)14(12):3403-11.

  • Rimsza L, Farinha P, Fuchs D, Masoudi H, Connors J, Gascoyne R. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma (2007) 48(3) 542-6.

  • Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg (2007).

  • Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol (2007)14(2),719.

  • Masoudi H, Van Niekerk DJ, Gilks CB, Cheang M, Bilek K, Fischer U, Ehlen T, Miller D, Horn LC. Loss of p16 INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. Histopathology (2006) 49(5), 542.

  • Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. Derangement of the Ecadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg (2006) 191(5),581.

  • Farinha P, Masoudi H, Skinnider B, Shumansky K, Spinelli J, Gill K, Klasa R, Voss N, Connors J, Gascoyne R. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood (2005) 106(6) 2169-74.



bottom of page